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Summary
Background: Sirtuin 1 (Sirt1) is suppressed in non-alcoholic fatty liver disease
(NAFLD), while its’ stimulation or overexpression results in reduced disease severity
in pre-clinical NAFLD models. Leucine allosterically activates Sirt1 and synergise
with other Sirt/AMPK/NO pathway activators. We developed a triple combination
of leucine, metformin and sildenafil (NS-0200), which was effective in a mouse
model of non-alcoholic steatohepatitis (NASH).
Aim: To report the results from a Phase 2, randomised clinical trial of of NS-0200
in 91 subjects with NAFLD (liver fat ≥15% by magnetic resonance imaging-proton-
density fat fraction (MRI-PDFF)).
Methods: Subjects were randomised to placebo, low-dose (1.1 g leucine/0.5 g met-
formin/0.5 mg sildenafil) or high-dose NS-0200 (1.1 g leucine/0.5 g metformin/
1.0 mg sildenafil) b.d. for 16 weeks; change in hepatic fat was assessed via MRI-
PDFF, and lipid metabolism was assessed via changes in the lipidomic signature.
Seventy subjects completed the trial and met a priori compliance criteria. Analyses
were conducted on the full cohort and on those with alanine aminotransferase
(ALT) values above median (50 U/L; n = 35).
Results: In the full cohort, active treatments did not separate from placebo. High
dose NS-0200 reduced hepatic fat by 15.7% (relative change from baseline) in the
high ALT group (P < 0.005) while low dose NS-0200 and placebo did not signifi-
cantly change hepatic fat. Lipidomic analysis showed dose-responsive treatment
effects in both overall and high ALT cohorts, with significant decreases in metaboli-
cally active lipids and up-regulation of fatty acid oxidation.
Conclusion: These data support further evaluation of high-dose NS-0200 for treat-
ing NASH, especially in those with elevated ALT (NCT 02546609).
The Handling Editor for this article was Professor Stephen Harrison, and it was accepted
for publication after full peer-review.
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1 | INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders
characterised by hepatic lipid accumulation and cellular degeneration,
in the absence of significant alcohol consumption or secondary
causes of hepatic steatosis.1 NAFLD includes those with non-
alcoholic steatohepatitis (NASH), who are most likely to develop
progressive fibrosis, cirrhosis and hepatocellular carcinoma. The
prevalence of NAFLD is 10%-25% in the general population, and
increases to ~ 75% in patients with obesity and diabetes.1-3 Cur-
rently, the most widely accepted view of the pathogenesis of
NAFLD is based on a “two-hit,” or a “multiple-hit” model, with insulin
resistance leading to hepatic lipid accumulation, representing the first
hit. Successive activation of multiple pathways resulting in oxidative
and inflammatory stress are thought to represent additional hit(s)
which mediate progression of disease and fibrosis;4,5 among individ-
uals with NAFLD, 23.8% are reported to have ≥F2 fibrosis and
2.3%-9.7% exhibit ≥F3 fibrosis.6 However, despite the pivotal role of
insulin resistance in the pathogenesis of NAFLD, improving insulin
sensitivity with metformin has only a minimal independent effect on
liver histology and therefore is not clinically recommended.1,7 There
is some evidence that pioglitazone improves NASH;8,9 however, that
primary outcome measure was not achieved in a large clinical trial.8
Furthermore, effects reported with pioglitazone do not appear to be
a thiazolidinedione-class effect, as rosiglitazone has not been effec-
tive in multiple clinical trials.9,10 There are presently no FDA-
approved therapeutic agents for treatment of NASH, although
weight loss exceeding 5%, whether via hypocaloric diet, exercise or
both improve hepatic steatosis, and more substantial weight loss
(~10%) may improve necroinflammation (sustained inflammation
leading to necrosis and fibrosis) as well.1,11
The 50 adenosine monophosphate-activated protein kinase
(AMPK)/Sirtuin 1 (Sirt1) pathway is a key regulator of mitochondrial
biogenesis, energy and lipid metabolism, including hepatic lipid meta-
bolism.12-17 Activation of this pathway via either enzyme prevents
or reverses excess hepatic lipid accumulation and inflammation,18-22
thus representing possible therapeutic targets for NASH. We have
demonstrated that L-leucine has a unique role as an activator of the
Sirt1/AMPK pathway,14,23,24 serving as a partial mimetic of caloric
restriction in pre-clinical models, and thereby modulates lipid and
energy metabolism and increases insulin sensitivity.
Consequently, adding L-leucine to metformin results in a novel,
synergistic interaction that enabled a 65%-80% metformin dose
reduction with no loss of anti-diabetic efficacy in diabetic rodent
models25,26 and a 40% metformin dose reduction in a recent clinical
trial.27 Moreover, this combination of leucine with low-dose met-
formin reversed hepatic steatosis in pre-clinical studies in murine
models of type 2 diabetes and NASH despite the lack of observed
effect of full-dose metformin in the absence of L-leucine,28 and add-
ing low-dose sildenafil synergistically enhances this effect by stimu-
lating endothelial nitric oxide synthase (eNOS) activity leading to
further stimulation of Sirt1, and thus further attenuating inflamma-
tion and fibrosis.15,29 Accordingly, this exploratory phase 2 study
was conducted to evaluate the efficacy of NS-0200, a leucine-
metformin-sildenafil fixed-dose combination, in reducing hepatic
steatosis and improving related metabolic parameters in a placebo-
controlled multicentre 16-week clinical trial.
2 | METHODS
2.1 | Study design
This was a randomised, placebo-controlled, phase 2, double-blind
study designed to evaluate the effects on hepatic steatosis of 2
fixed-dose combinations of leucine, metformin and sildenafil (NS-
0200) administered twice daily for 16 weeks, compared to placebo
(NCT 02546609). Active treatments consisted of capsules containing
1100 mg leucine, 500 mg metformin and either 0.5 or 1.0 mg silde-
nafil administered twice daily orally (Table 1).
Subjects were screened at clinical sites for basic eligibility criteria
with a detailed medical history and physical examination and blood
analysis 14 days prior to initiating the study. Those subjects who met
eligibility criteria returned for a screening magnetic resonance imaging
(MRI) exam to estimate hepatic fat fraction by proton-density fat frac-
tion (PDFF) within 7 days prior to study initiation. Participants with
hepatic fat fraction ≥15% by MRI-PDFF were enrolled in the study.
Participants who qualified by MRI-PDFF returned to the clinic on
study day 1 for baseline laboratories and first dose of study medica-
tion, followed by visits on days 7, 28, 56, 84 and 112 (end of study).
Subjects were also contacted by telephone on days 14, 42, 70 and 98
to enhance compliance. Study visits included routine blood tests,
body weight and assessment of compliance via pill counts, and the
final study visit included the endpoint MRI to assess PDFF change.
This study was approved by the Institutional Review Boards at
each participating centre, and written informed consent was
obtained from all participants prior to study enrolment and initiation
of study-specific procedures.
2.2 | Eligibility
The key inclusion criteria were age 18-75 years at study entry, MRI-
PDFF ≥15%, ALT ≥ 30 U/L for men and ≥ 19 U/L for women, body
mass index between 25 and 40 kg/m2 and clinical and laboratory cri-
teria consistent with NAFLD. Subjects with evidence of other
chronic liver disease or with history of significant alcohol consump-
tion, defined as >7 drinks/wk for both males and females for the
prior 6 months were excluded from the trial.
2.3 | Randomisation and blinding
A computer-generated randomised block schedule was prepared by
a third party, and treatment allocation was performed centrally for
all sites, with randomization numbers assigned in chronological order.
Study medication was provided to study centres in a blinded man-
ner, and sponsor personnel, study staff, MRI analysis staff and sub-
jects were blinded to treatment assignment.
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2.4 | Primary and secondary outcomes
The primary outcome was 16-week change in hepatic fat fraction,
estimated by MRI-PDFF. Secondary endpoints were 16-week
changes in liver enzymes (ALT, AST, GGT); cytokeratin 18 (K18, M30
epitope); HbA1c, fasting glucose, insulin and insulin sensitivity; blood
lipids (cholesterol, LDL, HDL and triglycerides); hsCRP; and serum
metabolomic profile.
2.4.1 | MRI acquisition
An MRI of the liver was performed using a torso-array surface coil
centred over the upper abdomen using one or both types of breath-
hold, noncontrast, gradient-recalled-echo, axial 2D sequence: a multi-
ple-echo (ME) 6-echo sequence, and a double-double-echo (DDE)
sequence. MRI-PDFF results from these2 types of sequence have
been shown to be nearly identical.30 Target MRI scanning parame-
ters were selected to avoid or correct for possible confounding fac-
tors (eg, T1 bias, T2* decay, multi-frequency interference) that could
introduce error in fat quantification.31-36 Images in Digital Imaging
and Communications in Medicine (DICOM) format were transferred
from clinical trial sites to a central Radiology Coordinating Center
(University of California at San Diego) for quality control (QC)
inspection, and analysis.
2.4.2 | MRI QC and analysis
After intake QC inspection of images and DICOM-header parameter
information, 3 circular, 1-cm radius regions of interest (ROIs) were
placed in the right lobe of liver, preferentially on fifth-echo liver
images for the ME sequence, and on the first-echo liver images of
the first DDE sequence, avoiding major vessels and ducts, lesions,
artefact, other organs and liver edges. Those ROIs were propagated
to images for the other echoes. ROI signal intensities from those
images were analysed with the MATLAB software analysis package
(MathWorks, Natick, MA) using a custom fitting algorithm that
assumed exponential T2* signal decay, and applied a multi-peak
spectral model to account for fat-fat and fat-water multi-frequency
interference effects, based on the work of Hamilton et al.37 MRI-
PDFF and effective transverse relaxation time (T2*) were calculated
for each ROI location. Values of MRI-PDFF, T2* and r2 (where ‘r’ is
the Pearson-r fitting coefficient for the custom fitting algorithm)
were recorded for each ROI, and mean values of the 3 ROI-location
PDFF values were recorded for each acquired sequence. To exclude
poorly fitted results, PDFF values for an ROI were excluded if the r2
fitting parameter was <.97.38
2.5 | Metabolomic assessment
Serum metabolomic profiles were semi-quantified by ultra-high per-
formance liquid chromatography coupled to mass spectrometry
(UHPLC-MS) as previously described.39 Briefly, 2 separate UHPLC-
Time of Flight-MS based platforms analysing methanol and chloro-
form/methanol serum extracts were combined with a UHPLC-single
quadrupole-MS based platform used to analyse amino acids. A speci-
fic metabolite extraction procedure was performed for each plat-
form. Identified ion features in the methanol extract platform
included fatty acids, acyl carnitines, bile acids, monoacylglycerophos-
pholipids, monoetherglycerophospholipids, free sphingoid bases,
N-acyl ethanolamines and oxidised fatty acids. The chloroform/
methanol extract platform provided coverage over glycerolipids,
cholesterol esters, sphingolipids, diacylglycerophospholipids and acyl-
ether-glycerophospholipids. Lipid nomenclature and classification fol-
lows the LIPID MAPS convention, www.lipidmaps.org. Metabolite
extraction procedures, chromatographic separation conditions and
mass spectrometric detection conditions are also detailed in.39 Meta-
bolomics data were pre-processed using the TargetLynx application
manager for MassLynx 4.1 (Waters Corp., Milford, MA). Intra-batch
(multiple internal standard response corrections) and inter-batch
(variable specific interbatch single point external calibration using
repeat extracts of a commercial serum sample) data normalisation is
described in.40
2.6 | Safety evaluation
Safety assessment included physical examination with vital signs,
12-lead electrocardiogram, clinical chemistry, haematology and uri-
nalysis. Adverse events were categorised by severity, outcome and
relationship to study drug.
2.7 | Statistics
The primary analysis population was per protocol (PP) for efficacy
endpoints and intention to treat (ITT) for safety endpoints. The PP
population consisted of all ITT subjects who completed all study vis-
its, had a valid MRI measured at the endpoint and who adequately
complied with the study protocol without major protocol deviations
and received ≥ 80% of provided study medication via pill counts. A
TABLE 1 Treatment arms
Treatment arm Subjects (N) randomised Dosing regimen
Study Medication Dosed Twice/Daya
Leucine Metformin Sildenafil
A 24 Placebo N/A N/A N/A
B 35 NS-0200 1100 mg 500 mg 0.5 mg
C 32 NS-0200 1100 mg 500 mg 1.0 mg
aAdministration was twice daily (b.d.); therefore, the total daily dose of NS-0200 is twice that listed for each component.
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post-hoc subgroup analysis consisting of participants with ALT levels
greater than median value (>50 U/L) was also conducted.
A mixed-model of analysis of covariance (ANCOVA) was used to
analyse changes in MRI-PDFF from baseline to week 16, with base-
line MRI-PDFF adjusted as a covariate. The least squares (LS) means,
standard errors (SEs) and the corresponding 95% confidence inter-
vals (CIs) for the changes from baseline to week 16 were derived
from the model for each treatment. Each of the fixed-dose combina-
tions of leucine, metformin and sildenafil treatment groups (low
dose, treatment group B; and high dose, treatment group C) were
compared to placebo group (treatment group A), and the LS means
for the treatment difference (treatment B or C minus treatment A),
the SEs, the associated 95% CIs and the P-values computed accord-
ingly; unless otherwise noted, all changes in MRI-PDFF are reported
as relative change, expressed as % change from baseline. Secondary
efficacy endpoints were similarly analysed via mixed effects model,
with baseline value used as covariate and with logarithmic transfor-
mation as necessary to ensure data normality.
Univariate analyses were performed on normalised metabolomic
data. These analyses consisted in several binary comparisons over
different defined subgroups of interest: paired comparisons between
study endpoint and baseline and unpaired comparisons between
treatment arms at baseline. For each metabolite, changes between
subgroups were calculated as the base 2 logarithm of fold-change
(mean of subgroup 1 divided by mean of subgroup 2). These values
were accompanied by a significance level based on P-values from
Student’s t-test. Three levels of increasing significance were consid-
ered: P < 0.05, P < 0.01 and P < 0.001. All calculations were per-
formed using statistical software package R v. 3.4.1 (R Core Team,
2017; https://www.R-project.org/). In order to visually compare
results, base 2 logarithm fold-changes and significances were used to
create detailed heatmaps, grouping metabolites by families.
Sample size requirements for the trial were initially estimated as
17/group based on 80% power to detect a mean treatment differ-
ence in MRI-PDFF, assuming a common standard deviation of 20%.
This sample size was increased by approximately 35%, to 23/treat-
ment group (69 total), to provide a larger sample size for assessment
of secondary endpoints. This value was then adjusted for a predicted
dropout rate of 24% to yield a final enrolment goal of 30/treatment
arm (90 total).
3 | RESULTS
Two hundred and fifteen subjects were screened for participation.
124 of these did not meet enrolment criteria, primarily due to hep-
atic fat fraction <15%. The remaining 91 subjects were randomised,
24 to placebo (treatment group A), 35 to the 1100 mg leucine/
500 mg metformin/0.5 mg sildenafil group (treatment group B) and
32 to the 1100 mg leucine/500 mg metformin/1.0 mg sildenafil
group (treatment group C). Of these, 90 participants received at least
one dose of medication and constituted the ITT analysis group.
Twenty of the enrolled (22.0%) participants discontinued study
treatment early; 2 from placebo (treatment group A, 8.3%), 11
(31.4%) from treatment group B and 7 (21.9%) from treatment group
C. Of the 71/91 (78.0%) participants completing the trial, 1 was
excluded from the PP analysis group due to non-adherence with a
priori study medication compliance criteria. Thus, a total of 70 par-
ticipants were analysed for this study for the PP group. Participants’
baseline characteristics are shown in Table2.
The relative change in MRI-PDFF between baseline and end of
treatment was 10  17.5% in the placebo treated patients,
whereas it was 3.08  25.5% in low-dose NS-0200-treated patients
(P = 0.057 compared to placebo) and 4.01  24.6% in high-dose
NS-0200-treated patients (P = 0.377 compared to placebo) (Fig-
ure 1). There were no significant changes in ALT, AST, GGT or K18
in any of the treatment groups. Body weight did not significantly
change in the placebo group (0.4 + 0.4 kg) or the low-dose NS-
0200 group (1.4  0.6 kg, not significant vs placebo); there was a
significant decrease in weight in the high-dose NS-0200 group
(2.4  0.5 kg, P = 0.025).
In a subgroup analysis, we examined the effects of high and low-
dose NS-0200 in participants with baseline ALT values above the
median (> 50 U/L; n = 35). In addition to elevated ALT levels (by
definition), this subgroup also had elevated K18, AST and GGT (Fig-
ure S1), as well as differential metabolomic profiling, as described
below. There was 15.7% relative reduction in MRI-PDFF in the high-
dose NS-0200 group in this high-ALT subgroup cohort (P = 0.0032),
while there was no significant change in either the lower dose or
placebo groups (Figure 2). In contrast, subjects with ALT below the
median value of 50 U/L exhibited a decrease in MRI-PDFF only in
the placebo group (20.5  5.7% relative decrease, P < 0.05 vs
active treatments), while those in the active treatment group exhib-
ited no significant change from baseline (low dose, 9.5  9.1%; high
dose, 4.3  6.1%),. Subjects with high baseline ALT exhibited non-
significant trends towards decreasing ALT and AST in the high-dose
NS-0200 group and significant reductions in GGT in both NS-0200
treatment groups vs placebo (Figure S2).
Although the study population was nondiabetic, both low- and
high-dose treatment arms achieved statistically significant reductions
in HbA1c (placebo adjusted decreases of 0.21% [P = 0.002] and
0.17% [P = 0.016] for low- and high-dose, respectively), but there
was no significant treatment effect on fasting glucose, insulin or
HOMA-IR.
Metabolomic profiling demonstrated reductions in metabolically
active lipids, including diglycerides (DG), triglycerides (TG), ceramides
and multiple phospholipid and sphingomyelins and glycerophospho-
lipid species in treatment vs placebo groups in the full per protocol
cohort at study endpoint vs baseline (Figure 3), and pathway analysis
of these data also demonstrate an increase in fat oxidation in the
active treatment groups. However, a comparison between partici-
pants with baseline ALT > 50 U/L and those with < 50 U/L ALT
demonstrated that only the high-ALT group exhibited treatment
effects on metabolically active lipids, as the low-ALT group exhibited
only minor increases in fatty acid species, but no treatment effect
on DG, TG, ceramides or other lipid species of interest (Figure 4).
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Furthermore, the baseline lipidomic signature between the high- and
low-ALT groups was different, with high-ALT subgroup exhibiting
more metabolically active lipid species indicative of greater baseline
disease.
Consistent with the improvements in lipidomic profile, there was
a corresponding improvement in TG which was most pronounced
among those with hypertriglyceridemia (≥ 200 mg/dL) at baseline
(n = 22; Figure S3).
Treatment-emergent adverse events (TEAEs) are summarised in
Table 3. Overall, the frequency of TEAEs was similar between pla-
cebo (75% of subjects) and pooled treatment groups (77% of sub-
jects). Similarly, comparable fractions of placebo (50%) and active
treatment (54.5%) subjects reported TEAEs that were considered
related to study treatment (Table 3). However, subjects in the active
treatment groups did report a greater number of mild-to-moderate
gastrointestinal events than the placebo group, including diarrhoea
(40.9 vs 8.3%), nausea (16.7 vs 12.5%) and vomiting (4.2 vs 0.6%),
consistent with the presence of metformin. There were no (0.0%)
serious TEAEs that were related to study treatment in any of the
treatment groups (placebo or NS-0200).
Subjects discontinued participation in the trial for the following
reasons: noncompliance/protocol violation(s), n = 5; withdrawal of
consent, n = 3; lost to follow-up, n = 5; and TEAEs, n = 7. TEAEs
leading to discontinuation are summarised in Table 4.
4 | DISCUSSION
Data from this exploratory randomised, placebo-controlled, phase 2,
double-blind clinical trial provide evidence supporting efficacy of NS-
0200 in a subset of subjects with NAFLD. Although the primary end-
point of reduced MRI-PDFF was not achieved in the pre-defined per
TABLE 2 Selected demographical and baseline characteristics by
treatmenta
Per protocol population (n = 70)
Placebo
treatment Ab
(n = 22)
NS-0200
treatment Bb
(n = 24)
NS-0200
treatment Cb
(n = 24)
Sex, n (%)
Male 11 (50.0) 8 (33.3) 12 (50.0)
Female 11 (50.0) 16 (66.7) 12 (50.0)
Age (y)c
Mean (SD) 46.7 (10.59) 45.7 (11.77) 46.0 (13.55)
Race, n (%)
American
Indian or
Alaska Native
0 (0.0) 0 (0.0) 1 (4.2)
Black or
African
American
2 (9.1) 1 (4.2) 0 (0.0)
White 19 (86.4) 22 (91.7) 22 (91.7)
White/Asian 1 (4.2) 1 (2.9) 0 (0.0)
Not Reported 0 (0.0) 1 (4.2) 1 (4.2)
Ethnicity, n (%)
Hispanic or
Latino
5 (22.7) 7 (29.2) 7 (29.2)
Not Hispanic
or Latino
17 (77.3) 17 (70.8) 17 (70.8)
Weight (kg)
Mean (SD) 98.16 (14.98) 94.21 (14.01) 96.70(17.84)
Height (cm)
Mean (SD) 170.5 (9.8) 169.8 (9.4) 168.6 (10.9)
Body Mass Index (BMI) (kg/m2)
Mean (SD) 33.82 (4.60) 32.62 (3.39) 33.62 (3.84)
Fasting Plasma Glucose (mg/dL)
Mean (SD) 109.1 (16.9) 103.0 (14.6) 112.1 (24.8)
HbA1c (%)
Mean (SD) 5.62 (0.45) 5.62 (0.57) 5.74 (0.71)
PDFF (%)
Mean (SD) 23.8 (4.7) 24.2 (7.0) 26.3 (6.0)
ALT (U/L)
Mean (SD) 64.0 (27.6) 56.5 (35.5) 55.5 (28.5)
AST (U/L)
Mean (SD) 37.4 (19.0) 33.1 (17.7) 34.1 (14.7)
GGT (U/L)
Mean (SD) 49.5 (29.3) 55.0 (44.4) 58.3 (33.7)
SD, Standard deviation; PDFF, Proton-density fat fraction; AST, Aspar-
tate aminotransferase; ALT, Alanine aminotransferase.
aNo statistically significant differences among treatment groups.
bTreatment A, Placebo; Treatment B, 1100 mg leucine + 500 mg met-
formin + 0.5 mg sildenafil; Treatment C, 1100 mg leucine + 500 mg
metformin + 1.0 mg sildenafil.
cAge at consent.
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F IGURE 1 Effects of treatments on PDFF in the full per protocol
cohort. A, Placebo; B, 1100 mg leucine/500 mg metformin/0.5 mg
sildenafil b.d.; C, 1100 mg leucine/500 mg metformin/1.0 mg
sildenafil b.d. PDFF changes are expressed as relative change from
baseline ([16 wk HFF-Baseline HFF]/Baseline HFF] X 100)
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protocol cohort, a post-hoc analysis indicates significant improve-
ments in MRI-PDFF in a cohort exhibiting more advanced disease
(P < 0.0032). The high-ALT cohort was defined as subjects with
baseline ALT above the median value of 50 U/L; although the higher
ALT levels in this cohort are not predictive of NASH per se, higher
ALT levels are nonetheless associated with both NASH and fibro-
sis.41,42 At baseline, this group had a 2-fold elevation in ALT vs the
low-ALT group, with corresponding elevations in other hepatic mark-
ers (AST, GGT and K18; Figure S1; P < 0.001). Further, this high-
ALT group exhibited a baseline metabolomic signature characteristic
of more pronounced disease 39 and exhibited decreases in multiple
metabolically active lipid species with treatment, while the low-ALT
group did not. These data are consistent with other reports demon-
strating minimal efficacy of experimental NASH therapeutics in indi-
viduals with mild disease vs greater efficacy in NASH resolution in
those with more advanced disease.43
The per protocol placebo group exhibited an unexpectedly high
placebo response which may have resulted from MRI-PDFF volatility
in less diseased individuals. Previous studies have demonstrated sim-
ilar volatility in hepatic fat, measured either via MRI-PDFF or mag-
netic resonance spectroscopy (MRS), and corresponding decreases in
liver fat in study placebo groups the absence of biopsy-confirmed
NASH. For example, Cui et al44 reported a 13.9% relative reduction
in MRI-PDFF in the placebo group of a 24-week study of sitagliptin
vs placebo in subjects with NAFLD. Similarly, in a shorter-term (12-
week) study of the effects of liraglutide and sitagliptin on hepatic fat
as measured by MRS in subjects with NAFLD, the placebo group
exhibited a 9.5% relative reduction from baseline in hepatic fat as
measured by MRS,45 consistent with the placebo group in the pre-
sent study. However, placebo-treated subjects with more advanced
disease, as evidenced by biopsy-confirmed NASH, exhibited only
4%-5% relative changes in MRI-PDFF,46,47 consistent with the
observed change in high-ALT cohort placebo group in the present
study.
Two doses of NS-0200 were evaluated, both containing 1.11 g
leucine and 500 mg metformin, and differing from each other only in
the quantity of sildenafil present (0.5 vs 1.0 mg). These sildenafil
doses were extrapolated from rodent data,15 accounting for species
differences in bioavailability. The lower dose produced little effect
on most variables, although it did result in improvements in the
metabolomics profile, while the higher dose produced improvement
in multiple variables. Thus, these data do not permit a conclusion
with respect to optimal sildenafil dose, and higher doses may be
warranted in follow-up studies. However, rodent studies (unpub-
lished data) indicates that > 4 mg sildenafil (human equivalent dose)
does not confer further benefit, and may in fact attenuate the effi-
cacy of this combination. The other components of NS-0200 have
been established at fixed levels, as follows. Pre-clinical data indicate
that optimal activation of Sirt1 occurs with a plasma leucine concen-
tration range of 0.38-0.50 mM,14,23-25 and dose-ranging studies with
oral leucine administration in adults demonstrate a linear dose rela-
tionship, with doses of 1.0-1.5 g resulting in peak plasma leucine
levels of 0.4-0.5 mM.48 Further increases in leucine administration
result in a slower increase, plateauing at ~ 0.8 mM,48 but this higher
level is associated with potential mTOR activation, while 0.5 mM
leucine is not.25 The metformin dose in NS-0200 is based on a pre-
vious assessment of leucine-metformin synergy in improving glyce-
mic control in patients with type 2 diabetes.27
The combination of leucine, metformin and sildenafil in NS-0200
targets a synergistic interaction among elements of the Sirt1-AMPK-
eNOS network.15 This network is a key regulator of integral factors
required for progression or regression of NASH, namely hepatic lipid
metabolism, oxidative stress and inflammation. Downregulation of
this system promotes NASH progression, while activation improves
hepatic steatosis, inflammation and fibrosis,19,49-51 and the combina-
tion of leucine, metformin and sildenafil correspondingly regressed
hepatic steatosis, inflammation, ballooning and fibrosis in a mouse
model of NASH.15 Synergy among the 3 components is evidenced
by the observation that the individual components in this combina-
tion exert little or no independent effect in experimental systems or
clinical studies. For example, the effects of metformin on liver fat
content, liver enzymes and/or histology have been evaluated in sev-
eral studies with little or no effect demonstrated.52-57 Further, a
recent systematic review57 of the effects of metformin on NASH
outcomes in 11 papers with pre- and post-treatment biopsies found
no histological improvement of NASH in nondiabetic adults (5 stud-
ies), in mixed populations of diabetic and nondiabetic adults (5 stud-
ies) or in adults with type 2 diabetes (1 study). Similarly, data from
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F IGURE 2 Effects of treatments on PDFF in subjects with elevated ALT (n = 35). A, Placebo (n = 14); B, 1100 mg leucine/500 mg
metformin/0.5 mg sildenafil b.d. (n = 11); C, 1100 mg leucine/500 mg metformin/1.0 mg sildenafil b.d. (n = 10). Left panel shows absolute
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F IGURE 3 Effects of NS-0200 on serum metabolomic changes in the per protocol cohort (n = 70). A, Placebo; B, 1100 mg leucine/500 mg
metformin/0.5 mg sildenafil b.i.d; C, 1100 mg leucine/500 mg metformin/1.0 mg sildenafil b.d. Comparisons are week 16 vs baseline. Green sections
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log2 fold-changes); grey/black bars indicate significant changes with treatment (light grey, P < 0.05; dark grey, P < 0.01; black, P < 0.001)
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F IGURE 4 Effects of NS-0200 on serum metabolomic changes in subjects with ALT > 50 U/L (“High ALT,” n = 35, left panel) vs those with
ALT< 50 U/L (“Low ALT,” n = 35, right panel). A, Placebo; B , 1100 mg leucine/500 mg metformin/0.5 mg sildenafil b.d.; C, 1100 mg leucine/
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children to adolescents also indicate little to no independent effect
of metformin; metformin exerted no effect on reducing ALT, hepatic
steatosis, lobular inflammation, NAFLD activity score or resolution of
NASH in the 96-week multicentre randomised trial (TONIC Trial) of
173 patients aged 8-17 years, although there was an improvement
in ballooning degeneration score.58
Similarly, although sildenafil has not been well-studied in NASH,
extensive pre-clinical and clinical studies do not demonstrate effects
of sildenafil on hepatic function in the approved therapeutic dose
range for labelled indications,59 and pre-clinical toxicology studies
demonstrate increases in absolute and relative liver weight in both rats
and dogs. Furthermore, El-Mahmoudy et al60 reported that adminis-
tration of sildenafil failed to protect against high fat diet-induced
impairment in hepatic biomarkers in hyperlipidemic rats. Thus, any
therapeutic benefit seen when sildenafil is administered as a compo-
nent of NS-0200 likely occurs as a result of synergy with leucine.
TABLE 3 Summary of treatment-emergent adverse events, by treatment group
Intent-to-treat population
(n = 90)
B and C Pooled
(n = 66)
Significance
(P value)
Placebo treatment Aa
(n = 24)
NS-0200 treatment Ba
(n = 34)
NS-0200
treatment Ca
(n = 32)
All TEAEsb 0.741
Number of subjects, n (%) 18 (75.0) 25 (73.5) 26 (81.3) 51 (77.3)
Number of events 49 91 90 181
All Serious TEAEs 0.435
Number of subjects, n (%) 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.5)
Number of events 0 3 0 3
All drug-related TEAEs 0.718
Number of subjects, n (%) 12 (50.0) 20 (58.8) 16 (50.0) 36 (54.5)
Number of events 20 54 39 93
All drug-related, serious TEAEs 1.000
Number of subjects, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Number of events 0 0 0 0
All TEAEs leading to study discontinuation 0.053
Number of subjects, n (%) 0 (0.0) 5 (14.7) 1 (3.1) 6 (9.1)
Number of events 0 5 1 6
aTreatment A, Placebo; Treatment B, 1100 mg leucine + 500 mg metformin + 0.5 mg sildenafil; Treatment C, 1100 mg leucine + 500 mg
metformin + 1.0 mg sildenafil.
bTreatment-emergent adverse event (TEAE) is defined as an adverse event occurring on or after the first dose of randomised study medication, or
existing prior to the time of and worsening after the time of the first dose of randomised study medication.
TABLE 4 Treatment-emergent adverse events leading to discontinuation by system organ class, preferred term and treatment
System organ class preferred term
n (%)
Intent-to-treat population (N = 90)
B and C pooled
(n = 66)
Significance
(P value)
Placebo treatment A
n = 24
NS-0200 treatment Ba
n = 34
NS-0200 treatment Ca
n = 32
All TEAEsb leading to discontinuation 0 (0.0) 6 (17.6) 1 (3.1) 7 (10.6) 0.0526
Eye disorders 0 (0.0) 2 (5.9) 0 (0.0) 2 (3.0) 0.186
Vision blurred 0 (0.0) 2 (5.9) 0 (0.0) 2 (3.0) 0.186
Gastrointestinal disorders 0 (0.0) 4 (11.8) 1 (3.1) 5 (7.6) 0.118
Diarrhoea 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.5) 0.435
Gastritis erosive 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.5) 0.435
Gastrointestinal disorder 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.5) 0.435
Nausea 0 (0.0) 1 (2.9) 1 (3.1) 1 (1.5) 0.689
aTreatment A, Placebo; Treatment B, 1100 mg Leucine + 500 mg Metformin + 0.5 mg Sildenafil; Treatment C, 1100 mg Leucine + 500 mg Met-
formin + 1.0 mg Sildenafil.
bTreatment-emergent adverse event (TEAE) is defined as an adverse event occurring on or after the first dose of randomised study medication, or exist-
ing prior to the time of and worsening after the time of the first dose of randomised study medication.
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Although leucine has not been well-studied in NASH, pre-clinical
data demonstrate little or no independent effect of leucine on either
histology or relevant biomarkers in mouse models of NAFLD/
NASH.15,29 Similarly, pre-clinical data demonstrate greater efficacy of
the leucine-metformin-sildenafil combination compared to combina-
tions of any two of these agents (leucine-metformin, leucine-sildena-
fil, metformin-sildenafil) in regressing hepatic steatosis, inflammation
and fibrosis in a mouse model of NASH.15 Thus, the efficacy of this
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F IGURE 5 Metabolomic assessment of baseline differences among treatment arms. A, Placebo; B, 1100 mg leucine/500 mg metformin/
0.5 mg sildenafil b.d.; C, 1100 mg leucine/500 mg metformin/1.0 mg sildenafil b.d. Comparisons shown are baseline of groups B+C vs A; B vs
A; C vs A; and C vs B. Green sections of the heat map denote metabolites that were reduced (negative log2 fold-changes) and red sections
denote metabolites that were increased (positive log2 fold-changes); grey/black bars indicate significant changes with treatment (light grey,
P < 0.05; dark grey, P < 0.01; black, P < 0.001)
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combination appears to be dependent upon synergistic interaction
among leucine, metformin and sildenafil.
Overall, NS-0200 was well-tolerated in this trial, with no dif-
ference in TEAEs in treatment vs placebo groups, although sub-
jects in the active treatment groups reported a greater number of
mild-to-moderate gastrointestinal events than the placebo group,
consistent with the metformin component of NS-0200.
This study has several limitations. Since the study was an
exploratory proof-of-concept study of relatively short duration, liver
biopsies could not be justified and therefore fibrosis and other histo-
logical outcomes cannot be assessed. Additionally, since subjects
were selected on the basis of MRI-PDFF (a quantitative biomarker
of hepatic steatosis) rather than biopsy-proven NASH, our study
probably included individuals with mild NAFLD unlikely to respond
to intervention. Additionally, the metabolomics data indicate hetero-
geneity in the extent of disease, with the placebo group presenting a
metabolic signature demonstrating lower levels of relevant metaboli-
cally active lipids (DG, TG, cholesterol esters, glycerophospholipids,
ceramides and sphingomyelins) than the 2 active treatment groups
(Figure 5), suggesting less advanced disease and possibly contribut-
ing to greater volatility in MRI-PDFF in the placebo vs active treat-
ment groups in the full cohort (per protocol) placebo group.
In conclusion, high-dose NS-0200 significantly reduced hepatic fat
in NAFLD patients with elevated ALT, and correspondingly improved
the NAFLD-associated metabolomic signature. NS-0200, either in
high or low dose, did not improve hepatic fat in the ITT population,
but the placebo-treated participants exhibited an unusually high
response rate. These data support further development of NS-0200,
especially high-dose NS-0200 in NAFLD patients with elevated ALT.
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